Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Aptose Biosciences Inc    APS   CA03835T2002

APTOSE BIOSCIENCES INC (APS)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
07/16/2018 07/17/2018 07/18/2018 07/19/2018 07/20/2018 Date
4.12(c) 4.43(c) 4.35(c) 4.41(c) 4.35 Last
56 125 34 410 23 872 11 611 4 363 Volume
-2.37% +7.52% -1.81% +1.38% -1.36% Change
More quotes
Financials (CAD)
Sales 2018 -
EBIT 2018 -29,0 M
Net income 2018 -29,1 M
Debt 2018 -
Yield 2018 -
Sales 2019 0,01 M
EBIT 2019 -31,1 M
Net income 2019 -32,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 16 271x
Capitalization 146 M
More Financials
Company
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies.Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG'806 a non-covalent small... 
More about the company
Latest news on APTOSE BIOSCIENCES INC
07/11Today's Research Reports on Emblem, OrganiGram, Oncolytics Biotech and Aptose..
AC
07/10Aptose Biosciences and CrystalGenomics Announce Issuance of Japanese Patent f..
GL
07/09Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncolo..
GL
06/29FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Tria..
GL
06/15Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematol..
GL
06/07APTOSE BIOSCIENCES INC : Today's Research Reports on Aptose Biosciences, Fennec ..
AC
06/05Aptose Biosciences Announces Results of Annual Meeting of Shareholders
GL
06/04Aptose Announces Two Publications of Preclinical Data Elucidating the Antican..
GL
05/31APTOSE Enters into US$20 Million Common Share Purchase Agreement with Aspire ..
GL
05/10Aptose Reports Results for the First Quarter Ended March 31, 2018
GL
More news
Sector news : Biotechnology & Medical Research - NEC
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07/10Aptose Biosciences and CrystalGenomics Announce Issuance of Japanese Patent f.. 
07/09Aptose Biosciences $APTO vs. PDL BioPharma $PDLI Head-To-Head Analysis  
07/09Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston On.. 
07/09Analyzing Aptose Biosciences $APTO & Vical $VICL  
07/07Head-To-Head Review: PDL BioPharma $PDLI & Aptose Biosciences $APTO  
More tweets
Qtime:9
News from SeekingAlpha
07/02Aptose Biosciences Back On Track In The Clinic 
07/02YOUR DAILY PHARMA SCOOP : Spectrum Trial Proceeds, AzurRx Moves To Phase 3, Apto.. 
06/303 THINGS IN BIOTECH, JUNE 30 : Aptose Gets Rolling Again; Tesaro Heads To China;.. 
06/29PREMARKET GAINERS AS OF 9 : 05 am (1/18/2018) 
06/29Aptos +12% after FDA lifts clinical hold on blood cancer drug trial 
Chart APTOSE BIOSCIENCES INC
Duration : Period :
Aptose Biosciences Inc Technical Analysis Chart | APS | CA03835T2002 | 4-Traders
Technical analysis trends APTOSE BIOSCIENCES INC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 9,21  CAD
Spread / Average Target 109%
EPS Revisions
Managers
NameTitle
William G. Rice Chairman, President & Chief Executive Officer
Gregory K. Chow Chief Financial Officer & Senior Vice President
Stephen B. Howell Chief Medical Officer
Ernest Kitt Vice President-Development & Technical Operations
Denis R. Burger Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
APTOSE BIOSCIENCES INC58.63%110
CELLTRION, INC.--.--%31 908
IQVIA HOLDINGS INC12.61%22 629
LONZA GROUP8.17%21 454
INCYTE CORPORATION-25.97%14 916
SEATTLE GENETICS, INC.31.81%10 764